Evidence of the Prognostic Value of Pretreatment Systemic Inflammation Response Index in Cancer Patients: A Pooled Analysis of 19 Cohort Studies

Table 2

Stratification analysis of the prognostic value of SIRI on OS in malignant tumors.

Subgroup	Number of cohorts	Pooled HR (95% CI)	Heterogeneity		Significance
			(%)	value
Altogether	17	2.30 (1.87-2.83)	73.1	0.000
Publishing year
2016-2017	4	2.27 (1.80-2.85)	0.0	0.978
2018-2019	13	2.33 (1.79-3.03)	79.6	0.000
Country
China	16	2.21 (1.80-2.72)	71.2	0.000
Spain	1	3.95 (2.47-6.30)	−	−
Sample number
<300	9	2.94 (2.47-3.50)	9.6	0.356
≥300	8	1.87 (1.48-2.37)	66.1	0.004
Method for cutoff selection
ROC analysis	13	2.01 (1.66-2.42)	58.4	0.004
X-tile software	4	3.56 (2.87-4.43)	0.0	0.577
Dividing line for SIRI
<1.17	7	2.04 (1.67-2.49)	17.8	0.294
≥1.17	10	2.43 (1.77-3.33)	82.5	0.000
Analytic method for HR
Multivariate	16	2.17 (1.80-2.62)	61.8	0.001
K-M	1	3.75 (2.67-4.60)	−	−
Stage
Metastatic	1	3.95 (2.47-6.30)	−	−
Nonmetastatic	8	1.68 (1.40-2.01)	34.4	0.153
Mixed	8	2.81 (2.30-3.44)	30.0	0.188
Treatment
With surgery	10	2.13 (1.58-2.87)	81.2	0.000
No surgery	7	2.58 (2.15-3.11)	0.0	0.571
Cancer system
Urinary	4	3.28 (2.34-4.60)	35.5	0.199
Respiratory	1	2.94 (1.56-5.52)	−	−
Digestive	10	1.93 (1.57-2.38)	64.3	0.003
Head and neck cancer	2	2.84 (1.86-4.32)	0.0	0.916
Follow-up
< 5 years	5	2.51 (2.02-3.13)	14.8	0.320
≥5 years	12	2.22 (1.69-2.91)	78.4	0.000